Your SlideShare is downloading. ×
Jay OMICS FDA ESG Presentation
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Jay OMICS FDA ESG Presentation

284

Published on

Common regulatory issues and challenges in dealing with eSubmissions through FDA electronic submissions gateway.

Common regulatory issues and challenges in dealing with eSubmissions through FDA electronic submissions gateway.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
284
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Common regulatory issues and challenges in dealing with eSubmissions through FDA electronic submissions gateway Jayprakash Sr. Project Leader Nov. 2012
  • 2. DisclaimerWhile every effort is made by the author toensure that all the information provided isaccurate and solely for the informationpurpose only, the author accepts noliability for the consequences of anyactions taken on the basis of theinformation provided. Any views or opinionspresented in this research study are solelythose of the author and do not necessarilyrepresent any company or agency.
  • 3. Introduction The Food and Drug Administration (FDA) Electronic Submissions Gateway (ESG) is an Agency-wide solution for accepting electronic regulatory submissions. Implementation of FDA ESG into production in May, 2006. In 2006 itself, FDA ESG received 58,664 electronic submissions for AERS, CDER, CBER & CDRH Centers. Improves cost savings, reduce resource requirements, and time efficiencies for both Sponsors and the Agency. OC started receiving SPL submissions from 2008 and became a mandate after 30 June 2009. OC received a total of 173,732 electronic submissions till now.
  • 4. Constraints The FDA ESG does not review submissions and only automatically routes documents to the chosen Office or Center. Users often face common validation issues due to either user discrepancy or new FDA guidelines. A failed submission creates a chain of resubmissions. Delays the product approval causing severe impact on the business of the company. A failed electronic submission requires additional resources to fix it. Resubmission adds up additional cost to the company. Multiple resubmissions from various users increase additional traffic on the gateway which impacts its efficiency and consistency.
  • 5. Case Study To identify the factors which cause validation errors during electronic submissions made to OC for SPL documents. Aim was to take preventive and corrective actions (CAPA) and a control plan to achieve at least 95% success rate for electronic submissions made to FDA ESG OC Center during first attempt. Project CharterBUSINESS CASE This company submitted total 119 Structured Product Labeling documents to FDA ESG from Oct 2009 to Mar 2011, Out of which 65 passed and 54 SPL documents failed the FDA ESG Validation. This higher ratio of failures is affecting the SPL conversion Turnaround time, Productivity, Customer Satisfaction and may result in Loss of Services Contract.PROBLEM STATEMENT The SPL Consulting Team has received numerous grievances from the customer regarding frequent SPL failures at FDA ESG and delayed approvals for their product. Failure to create/convert total compliant SPL ,negatively impacts customer satisfaction and increases cost to both the company business and the customer.GOAL STATEMENT To improve the SPL submission success rate from 54.62% to 95% by Dec 2011 and reduce the SPL conversion Turnaround time to 5 days.
  • 6. Case Study The current Sigma value (Z) before the implementation of the Green Belt project.Details Symbols ValuesDefect opportunities per Unit O = 1Number of units processed N = 119Total number of defects made D = 54(include defects made and later fixed)Defects Per Opportunity DPO = D/N*O 0.453781513Yield (1-DPO)*100 54.62Process Sigma (Short term) Z = 1.6
  • 7. Case Study The number of errors after implementation of the Green Belt Project was reduced drastically.STATISTICAL PROCESS CONTROL – SPL DOCUMENT TYPE Before After SPL Document Types SPL Document Types Failed Total Submitted Failed Total Submitted 79 76 41 29 22 14 12 9 4 2 0 0 LCR ERF SPL LCR ERF SPL
  • 8. Case Study The % of defective items was reduced by 96% from 45.38% to 1.77%.BINOMIAL CAPABILITY COMPARISON
  • 9. Case Study By implementing the new proposed solution the process sigma improved from 1.6 Sigma to 3.6 sigma.Details Symbols Before AfterDefect opportunities per Unit O= 1 1Number of units processed N= 119 113Total number of defects made D= 54 2(include defects made and later fixed)Defects Per Opportunity DPO = D/N*O 0.453781513 0.017699Yield (1-DPO)*100 54.62 98.23Process Sigma (Short term) Z= 1.6 3.6
  • 10. Current Scope Six Sigma Green Belt Project was done only for the SPL submissions made to OC by a Regulatory Compliance vendor. Submission made by all users to all the FDA Centers are prone to much more issues. If all these submissions made to all FDA Centers are monitored and assessed for submission failures, the scope for improvement will definitely be massive. A total of 3,806,019 electronic submissions were made to FDA ESG till now. In 2012 itself, 1,166,872 electronic submissions made to FDA ESG.
  • 11. Submission Statistics2006 - 2012 2006 2007 2008 2009 2010 2011 2012 Totals Totals AERS 55,156 159,562 252,614 300,672 472,142 557,917 595,182 2,393,245 CDER 1,639 11,175 24,797 45,510 69,739 93,503 88,367 334,730 CBER 294 1,504 2,557 4,483 5,588 6,397 5,736 26,559 CDRH 1,575 1,527 4,619 21,296 119,087 280,312 390,355 818,771 CVM 288 843 859 945 17,932 30,268 51,135 OC 188 16,275 48,232 55,676 53,361 173,732 CTP 5 223 348 520 1,096 MWP 1,138 2,530 2,361 6,029 ACA 53 53 GDUFA 669 669 Totals 58,664 174,056 285,618 389,100 717,094 1,014,615 1,166,872 3,806,019
  • 12. Future Trends FDA ESG is the most advanced & busiest gateway. Scope to move to the next level of electronic submissions going forward. With Artificial Intelligence, the role of FDA ESG can be enhanced to handle complex validation rules and automate major of the review system to process the electronic submission at much faster pace. With Auto Correction feature, FDA ESG will fix minor issues to save time, effort and cost. FDA ESG Auto Renewal component will renew the recurring renewal submissions and reduce load on the system. An integrated ESG can help the companies with single submission multiple approvals for different countries. The performance reports based on each user with passed and failed status can be introduced to help them assess their proficiency.
  • 13. Conclusion The scope is wide open and confirms the issues focused are only the tip of the iceberg. This electronic submission process needs more consideration and shall be open for further analysis. Goal shall be to enhance all the electronic submissions made to FDA ESG at 95 % success rate at the first attempt itself. Electronic submissions validated during first attempt will eliminate the need for resubmissions. Companies can save on Cost, Effort & Time required to fix the failed electronic submissions at FDA ESG. Lessen the burden on the gateway, increasing its efficiency and consistency.
  • 14. Courtesy FDA.gov : http://www.fda.gov/ForIndustry/ElectronicSubmissionsGateway/ucm1 10653.htm Professional Services Group – Virtify Inc. (http://www.virtify.com) Getting started with the FDA’s electronic submissions gateway - (Regulatory Rapporteur – Vol 7, No 9, September 2010)
  • 15. Questions & Answers Jayprakashreddy Reddyjayprakash

×